Determination of candesartan cilexetil, candesartan and a metabolite in human plasma and urine by liquid chromatography and fluorometric detection.
Liquid chromatographic methods are described for the determination of a new effective anti-hypertensive drug candesartan (CV-11974), its prodrug candesartan cilexetil (TCV-116) and a metabolite, CV-15959 in human plasma and urine. The assays comprise liquid-liquid extraction and separation on a phenyl column with fluorometric detection. The methods give absolute recoveries of 70, 83 and 78% for candesartan cilexetil, candesartan and CV-15959, respectively, and the limit of quantification is 5, 1 and 3 nM of plasma (RSD < 20%), respectively. The methods were applied to plasma and urine samples from biopharmaceutical and clinical studies in man.
Stenhoff
H
H
Astra Zeneca R&D Mölndal, Sweden.
Lagerström
P O
PO
Andersen
C
C
D000959:Antihypertensive Agents / Q000097:blood / Q000493:pharmacokinetics / Q000652:urine; D001562:Benzimidazoles / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D001713:Biphenyl Compounds / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D002853:Chromatography, Liquid / Q000379:methods*; D006801:Humans; D011355:Prodrugs / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013050:Spectrometry, Fluorescence; D013777:Tetrazoles / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine
D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D011355:Prodrugs; D013777:Tetrazoles; C077793:candesartan cilexetil; C081643:candesartan